image credit- shutterstock
NEC Orchestrating Future Fund, an ecosystem-based corporate venture capital (CVC) fund, has invested in Aetion, Inc., a US-based provider of healthcare platforms. In addition, NEC and Aetion have started discussions for collaboration in the Real World Data (RWD) / Real World Evidence (RWE) business in drug development.
The Aetion Evidence Platform (AEP) is utilised by numerous organisations worldwide, including pharmaceutical companies, regulatory authorities, insurers, and healthcare institutions. AEP enables the standardisation, quality assurance, and transparency of RWD, facilitating rapid and accurate analysis from a wide variety of data sources. Additionally, it transforms RWD using scientifically validated methods to generate reliable RWE. This approach addresses the challenges associated with RWD/RWE utilization and supports effective decision-making.
Japan-based NEC aims to address medical and healthcare challenges and create new value through its healthcare and life sciences business, including electronic medical records. Aetion has a highly reliable and proven track record in evaluating the efficacy and safety of pharmaceuticals. Synergies between the two companies have the potential to improve the efficiency of the drug development process and the creation of new treatment methods. This investment enables NEC and Aetion to further explore business collaboration in the RWD/RWE business in drug development.
